A promising study from AstraZeneca

Preliminary results from Astra Zeneca’s COAST Phase II trial shows that anti-CD73 therapy, developed by Dr. John Stagg and his team, increases the efficacy of IMFINZI (durvalumab) in lung cancer patients. His discoveries led to the development of several therapeutic agents targeting the adenosine pathway.